Clinical Trial Update: Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the combination of 3F8 (Iodine-131 labeled monoclonal antibody) and bevacizumab in relapsed or refractory neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 3F8
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED